Posted by Michael Wonder on 01 Apr 2021
European Commission approves Cabometyx in combination with Opdivo as a first-line treatment for patients living with advanced renal cell carcinoma
31 March 2021 - Approval based on pivotal Phase 3 CheckMate-9ER trial data, also recently published in the New England Journal of Medicine.
Ipsen today announced that the European Commission has approved Cabometyx (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo (nivolumab) for the first-line treatment of advanced renal cell carcinoma.
This decision marks the first approval for Cabometyx in combination with another therapy in Europe and the third indication of Cabometyx in renal cell carcinoma.
